Spyre Therapeutics, Inc. (SYRE)
36.63
+1.79
(+5.14%)
USD |
NASDAQ |
Feb 13, 16:00
36.65
+0.02
(+0.05%)
After-Hours: 20:00
Spyre Therapeutics Cash from Investing (Quarterly) : 25.00M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| PTC Therapeutics, Inc. | -289.62M |
| ACADIA Pharmaceuticals, Inc. | -79.35M |
| Alnylam Pharmaceuticals, Inc. | -37.17M |
| Savara, Inc. | 21.47M |
| BioMarin Pharmaceutical, Inc. | -330.96M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -37.12M |
| Cash from Financing (Quarterly) | -4.643M |
| Free Cash Flow | -162.30M |
| Free Cash Flow Per Share (Quarterly) | -0.6107 |
| Free Cash Flow to Equity (Quarterly) | -37.12M |
| Free Cash Flow to Firm (Quarterly) | -37.12M |
| Free Cash Flow Yield | -7.48% |